Your browser version may not work well with NCBI's Web applications. More information here...
1: Neuroreport. 2006 Nov 27;17(17):1793-6. Links

Effects of a novel tripeptide on neurological outcomes after spinal cord injury.

John SM, Bao F, Chen Y, Mathison RD, Weaver LC.

Spinal Cord Injury Team, BioTherapeutics Research Group, Robarts Research Institute, London, Ontario, Canada.

A biologically active tripeptide [phenylalanine glutamate glycine (feG)] derived from the submandibular gland has anti-inflammatory actions. We have shown that intravenous treatment with feG after spinal cord injury decreases the intraspinal infiltration of leukocytes and associated oxidative damage within 72 h after injury. The present study assessed effects of this treatment on chronic neurological outcomes after clip-compression spinal cord injury at the 12th thoracic segment. Locomotor scores of feG-treated rats were significantly higher than those of controls at 7 weeks after spinal cord injury. Treated rats had significantly less hind paw mechanical allodynia than controls at this time. In conclusion, the anti-inflammatory and anti-oxidative actions of feG treatment correlate with improved neurological outcomes after spinal cord injury.

PMID: 17164666 [PubMed - indexed for MEDLINE]